Scarica l'app Stockscreener
0.7343
5.86%
-0.0457
Dopo l'orario di chiusura:
.73
-0.0043
-0.59%
Precedente Chiudi:
$0.78
Aprire:
$0.7775
Volume 24 ore:
484.96K
Relative Volume:
0.24
Capitalizzazione di mercato:
$14.05M
Reddito:
-
Utile/perdita netta:
$-12.47M
Rapporto P/E:
-0.8059
EPS:
-0.9111
Flusso di cassa netto:
$-10.10M
1 W Prestazione:
-2.08%
1M Prestazione:
-8.85%
6M Prestazione:
-47.17%
1 anno Prestazione:
-13.83%
Intervallo 1D:
$0.7118
$0.7775
Intervallo di 1 settimana:
$0.7118
$0.81
Portata 52W:
$0.4894
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Nome
Hoth Therapeutics Inc
Settore
Industria
Telefono
(646)756-2997
Indirizzo
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.7343 | 14.92M | 0 | -12.47M | -10.10M | -0.9111 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-10-15 | Iniziato | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie
Why is HOTH stock up 70% after-hours today? - MSN
HOTH Should I Buy - Intellectia AI
Exclusive: Hoth Therapeutics targets faster drug discovery with new AI platform - MSN
HOTH Technical Analysis | Trend, Signals & Chart Patterns | HOTH THERAPEUTICS INC (NASDAQ:HOTH) - ChartMill
HOTH Hoth Therapeutics Inc. posts wider than expected Q4 2025 loss even as shares climb nearly 8 percent in today's trading.Decline Risk - Cổng thông tin điện tử tỉnh Tây Ninh
Hoth Therapeutics, Inc.Common Stock (NQ: HOTH - The Chronicle-Journal
Hoth Therapeutics Is A High-Risk Biotech Betting On Trial Milestones - Finimize
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Hoth Therapeutics Files 8-K with SEC Detailing Legal Opinion for NASDAQ-Listed Common Stock (HOTH) - Minichart
Hoth Therapeutics Resumes At-the-Market Equity Offering Program - TipRanks
Hoth Therapeutics to resume at-the-market offering with new prospectus filing - Investing.com
Hoth Therapeutics (NASDAQ: HOTH) to restart at-the-market stock program - Stock Titan
Hoth Therapeutics (NASDAQ: HOTH) files ATM prospectus to raise up to $1.56M - Stock Titan
Hoth Therapeutics Reports Positive HT VA Study Data Highlighting GDNF Driven Metabolic Reprogramming In Fatty Liver Disease - BioPharma APAC
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Emerging Now: ANY, GPRO, HOTH, SNAL Shift Strategic Focus in 2026 - openPR.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Move Over Novo NordiskThis Small Company Study Flags Edge In Fatty Liver Drug - Benzinga
Positive Results for Hoth Therapeutics (HOTH) in Liver Disease S - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Hoth reports preclinical data on GDNF for fatty liver disease By Investing.com - Investing.com South Africa
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide - Eastern Progress
Trending Stocks Today | Perfect Moment Surges 88.88% Pre-Market - Moomoo
Hoth Therapeutics Reports Positive GDNF Data for Fatty Liver Disease - National Today
Why Is HOTH Stock Up 70% After-Hours Today? - Stocktwits
Hoth Therapeutics (Hoth) Reports Positive Ht-Va Crada Data Gdnf Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene And Activates Fat-Burning Pathways, Outperforming Semaglutide - TradingView — Track All Markets
Hoth Therapeutics announces issuance of Chinese patent for cancer cell-targeting technology - Select Science
HOTH.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
HOTH Q4 2025 Earnings: Hoth Therapeutics misses EPS estimates with zero revenueExpert Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Aug Update: Is Hoth Therapeutics Inc benefiting from innovation trends2026 Decliners & High Accuracy Investment Entry Signals - baoquankhu1.vn
HOTH.O Technical Analysis & Stock Price Forecast - Intellectia AI
Trend Report: Is Hoth Therapeutics Inc stock trending bullish2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
HOTH.O PE Ratio & Valuation, Is HOTH.O Overvalued - Intellectia AI
HOTH.O Forecast — Price Prediction for 2026. Should I Buy HOTH.O? - Intellectia AI
HOTH.O - Reuters
Is Hoth Therapeutics (HOTH) Stock in a Selling Zone | Price at $0.59, Up 4.29%Fundamental Analysis - Cổng thông tin điện tử tỉnh Lào Cai
Guidance Update: Whats the fair value of Hoth Therapeutics Inc stock2026 Earnings Surprises & Stock Timing and Entry Methods - baoquankhu1.vn
Hoth Therapeutics Completes Registered Direct Offering Financing - The Globe and Mail
Hoth Therapeutics, Inc. (HOTH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Hoth Therapeutics, Inc. (HOTH) stock price, news, quote and history - Yahoo Finance UK
Hoth Therapeutics closes $2 million registered direct offering By Investing.com - Investing.com Canada
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering - Lelezard
Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):